HYDERABAD, India, Feb. 5, 2026 /PRNewswire/ -- According to Mordor Intelligence, the proteomics market size was valued at USD 29.92 billion in 2025 and projected to grow from USD 33.47 billion in 2026 to reach USD 58.66 billion by 2031, at a CAGR of 11.87% during the forecast period (2026-2031). The market expansion is supported by the growing focus on precision medicine, increasing prevalence of chronic diseases, and rising demand for advanced analytical tools to understand complex biological systems.  Th ...

Lawhive, a British startup that wants to use AI to transform the business model of law firms that perform routine legal work for individuals and small businesses, has raised $60 million in new venture capital funding to accelerate its expansion in the U.S.The Series B funding round was led by Mitch Rales, cofounder of Danaher Corporation, the $170 billion science and technology conglomerate. Other investors included TQ Ventures, GV (formerly Google Ventures), Balderton Capital, and Jigsaw. The funding comes ...

Jan. 28 was a pretty painful day for shareholders of Danaher Corporation ( DHR ). Shares of the stock dropped 4.8% after management announced financial results covering the final quarter of the company's 2025 fiscal year. Although it looks as thoughDaniel is an avid and active professional investor. He runs Crude Value Insights, a value-oriented newsletter aimed at analyzing the cash flows and assessing the value of companies in the oil and gas space. His primary focus is on finding businesses that are trad ...

Core Insights - Danaher reported a revenue of $24.568 billion for 2025, representing a 3.0% increase from $23.875 billion in 2024, with core business growth of 2.0% and a 1.0% contribution from currency fluctuations [2] - The company generated a free cash flow of $5.293 billion in 2025, demonstrating strong cash generation capabilities [1][3] Financial Performance - In Q4 2025, revenue reached $6.838 billion, a 4.5% increase from $6.538 billion in Q4 2024, with core business growth contributing 2.5% and currency fluctuations contributing 2.5% [2] - Adjusted operating profit margin for Q4 was 28.3%, down 130 basis points from 29.6% in Q4 2024; the full-year adjusted operating profit margin was 28.2%, a slight decrease of 40 basis points from 28.6% in 2024 [3] - Adjusted diluted earnings per share for Q4 was $2.23, a 4.0% year-over-year increase, while the full-year adjusted diluted earnings per share was $7.80, up 4.5% [3] Business Segment Performance - The Biotechnology segment led growth with Q4 revenue of $2.033 billion, a 9.0% year-over-year increase, and full-year revenue of $7.293 billion, an 8.0% increase [4] - The Life Sciences segment reported Q4 revenue of $2.085 billion, a 2.5% increase, with full-year revenue remaining stable at $7.334 billion [5][6] - The Diagnostics segment achieved Q4 revenue of $2.720 billion, a 3.0% increase, with full-year revenue of $9.941 billion, reflecting a 1.5% growth [7] 2026 Guidance - For 2026, Danaher expects core sales to grow between 3.0% and 6.0%, with the Biotechnology segment projected to grow approximately 6.0% [8] - The company anticipates adjusted diluted earnings per share to be between $8.35 and $8.50, with an adjusted operating profit margin of around 28.5% [8] Market Outlook - Danaher's CEO highlighted signs of recovery in the end markets served, particularly in the pharmaceutical sector, with strong demand for monoclonal antibody production and improvements in capital expenditure [9]

Core Insights - Danaher Corporation is recognized as a global leader in science and technology, particularly in Life Sciences, Diagnostics, and Biotechnology, outperforming competitors like Thermo Fisher Scientific and Agilent Technologies [1] - Analyst Vijay Kumar from Evercore ISI has set a price target of $254 for Danaher, suggesting a potential upside of 13.15% from its current stock price of $224.48 [1] Financial Performance - In the fourth quarter, Danaher reported an adjusted EPS of $2.23, slightly exceeding the Zacks Consensus Estimate of $2.22, with net sales of $6.84 billion, surpassing expectations of $6.79 billion, reflecting a year-over-year increase of 4.5% [2][6] - The Biotechnology segment saw a revenue increase of 9%, while Diagnostics profits rose by 14.3% [3] - For the full year 2025, Danaher achieved net revenues of $24.6 billion, a 3% increase from the previous year, with core sales growing by 2.5% in the fourth quarter [3][6] Future Outlook - Danaher has provided an optimistic earnings guidance for 2026, expecting low single-digit core sales growth in the first quarter and projecting an adjusted EPS between $8.35 and $8.50, indicating confidence in its growth trajectory [4] Stock Performance - Currently, Danaher's stock price is $224.48, reflecting a decrease of 4.78% or $11.28, with fluctuations between $223.09 and $235.07 on the day [5] - Over the past year, the stock reached a high of $242.80 and a low of $171, with a market capitalization of approximately $160.74 billion and a trading volume of 6.42 million shares [5]

Core Viewpoint - Danaher Corporation is experiencing strong financial performance, leading to a positive outlook from Evercore ISI, which has maintained an "Outperform" rating and raised its price target to $254 [1][6]. Financial Performance - Danaher reported fourth-quarter adjusted earnings per share (EPS) of $2.23, slightly exceeding the Zacks Consensus Estimate of $2.22 [2]. - Net sales for the quarter reached $6.84 billion, surpassing expectations of $6.79 billion, marking a 4.5% increase from the previous year [2]. - For the full year 2025, Danaher achieved net revenues of $24.6 billion, reflecting a 3% year-over-year increase [3]. Segment Performance - The Biotechnology segment saw a revenue surge of 9%, while the Diagnostics segment experienced a profit increase of 14.3% [3]. - The company projects low single-digit core sales growth in the first quarter of 2026, with adjusted EPS expected to range from $8.35 to $8.50 [3][6]. Stock Performance - Danaher's stock is currently priced at $223.995, reflecting a decrease of approximately 4.99% with a change of -$11.75 [4]. - The stock has fluctuated between a low of $223.09 and a high of $235.07 today, with a market capitalization of approximately $160.39 billion [4]. Market Dynamics - Foreign-currency translations positively impacted the quarter's results by 2.5%, while acquisitions and divestitures had a slight negative effect of 0.5% [5]. - The trading volume for the day is 5,105,026 shares on the NYSE, indicating active investor interest [5].

Group 1 - Danaher Corporation reported fourth-quarter results that exceeded analyst expectations, with adjusted earnings of $2.23 per share and revenue of $6.84 billion, reflecting a year-over-year revenue increase of 4.5% [1] - The company's non-GAAP core revenue increased by 2.5%, driven by strong performance in bioprocessing [1] Group 2 - For the full year 2025, Danaher achieved adjusted earnings of $7.80 per share, marking a 4.5% growth, and revenue of $24.6 billion, which is a 3.0% increase from the previous year [2] - The company generated $6.4 billion in operating cash flow and $5.3 billion in non-GAAP free cash flow [2] Group 3 - Looking ahead, Danaher anticipates low-single-digit core revenue growth in the first quarter of 2026 [3] - For the full year, the company forecasts core revenue growth of 3% to 6% and adjusted earnings between $8.35 and $8.50 per share, with the midpoint slightly above the analyst consensus of $8.42 [3]

Key Takeaways DHR beat Q4 estimates as adjusted EPS hit $2.23 and revenues rose 4.5% year over year.DHR saw broad segment growth, led by Biotechnology revenues up 9% and Diagnostics profit up 14.3%.DHR expects low single-digit core sales growth in Q1 2026 and adjusted EPS of $8.35-$8.50.Danaher Corporation’s (DHR) fourth-quarter 2025 adjusted earnings of $2.23 per share beat the Zacks Consensus Estimate of $2.22. The bottom line increased 4% year over year.Danaher reported net sales of $6.84 billion, which ...

For the quarter ended December 2025, Danaher (DHR) reported revenue of $6.84 billion, up 4.6% over the same period last year. EPS came in at $2.23, compared to $2.14 in the year-ago quarter.The reported revenue represents a surprise of +0.64% over the Zacks Consensus Estimate of $6.79 billion. With the consensus EPS estimate being $2.22, the EPS surprise was +0.68%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their nex ...

Molecular diagnostics (Cepheid): FDA clearance for the Xpert GI Panel, a multiplex PCR test that detects 11 gastrointestinal pathogens from a single sample using the GeneXpert platform.Diagnostics (Beckman Coulter Diagnostics): Expansion of the DxI 9000 assay menu, including progress in neurodegenerative disease and a first-to-market automated high-throughput BD-Tau research-use-only immunoassay, alongside additions in cardiac and blood virus menus.Life sciences (SCIEX): Introduction of the ZenoTOF 8600 mas ...